371 related articles for article (PubMed ID: 30591531)
1. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Tang H; Liu Y; Wang C; Zheng H; Chen Y; Liu W; Chen X; Zhang J; Chen H; Yang Y; Yang J
J Pharmacol Exp Ther; 2019 Mar; 368(3):401-413. PubMed ID: 30591531
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells.
Suda K; Rozeboom L; Rivard CJ; Yu H; Ellison K; Melnick MAC; Hinz TK; Chan D; Heasley LE; Politi K; Mitsudomi T; Hirsch FR
Lung Cancer; 2017 Jul; 109():1-8. PubMed ID: 28577937
[TBL] [Abstract][Full Text] [Related]
4. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade.
Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA
Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064
[TBL] [Abstract][Full Text] [Related]
5. Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.
Shimizu K; Okita R; Saisho S; Maeda AI; Nojima Y; Nakata M
Anticancer Res; 2018 Aug; 38(8):4637-4644. PubMed ID: 30061230
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers.
Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF
Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369
[TBL] [Abstract][Full Text] [Related]
7. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC.
Li X; Lian Z; Wang S; Xing L; Yu J
Cancer Lett; 2018 Apr; 418():1-9. PubMed ID: 29309815
[TBL] [Abstract][Full Text] [Related]
8. [Effects of anti-PD-L1 monoclonal antibody and EGFR-TKI on the expression of PD-L1 and function of T lymphocytes in EGFR-mutated lung cancer cells].
She Y; Pan X; Xing YF; Zhou T; Zhang ZL; Shi MH; Chen YJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):886-892. PubMed ID: 27998463
[No Abstract] [Full Text] [Related]
9. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Jiang Z; Yang Y; Yang Y; Zhang Y; Yue Z; Pan Z; Ren X
Biomed Pharmacother; 2017 Dec; 96():378-383. PubMed ID: 29031195
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of galectin-3 augments the antitumor efficacy of PD-L1 blockade in non-small-cell lung cancer.
Zhang H; Liu P; Zhang Y; Han L; Hu Z; Cai Z; Cai J
FEBS Open Bio; 2021 Mar; 11(3):911-920. PubMed ID: 33455075
[TBL] [Abstract][Full Text] [Related]
11. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Jiang ZB; Wang WJ; Xu C; Xie YJ; Wang XR; Zhang YZ; Huang JM; Huang M; Xie C; Liu P; Fan XX; Ma YP; Yan PY; Liu L; Yao XJ; Wu QB; Lai-Han Leung E
Cancer Lett; 2021 Sep; 515():36-48. PubMed ID: 34052328
[TBL] [Abstract][Full Text] [Related]
12. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Akbay EA; Koyama S; Carretero J; Altabef A; Tchaicha JH; Christensen CL; Mikse OR; Cherniack AD; Beauchamp EM; Pugh TJ; Wilkerson MD; Fecci PE; Butaney M; Reibel JB; Soucheray M; Cohoon TJ; Janne PA; Meyerson M; Hayes DN; Shapiro GI; Shimamura T; Sholl LM; Rodig SJ; Freeman GJ; Hammerman PS; Dranoff G; Wong KK
Cancer Discov; 2013 Dec; 3(12):1355-63. PubMed ID: 24078774
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
14. Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
Rugamba A; Kang DY; Sp N; Jo ES; Lee JM; Bae SW; Jang KJ
Cells; 2021 Jun; 10(7):. PubMed ID: 34209829
[TBL] [Abstract][Full Text] [Related]
15. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT
Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963
[TBL] [Abstract][Full Text] [Related]
16. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
17. Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.
Liu H; Deng R; Zhu CW; Han HK; Zong GF; Ren L; Cheng P; Wei ZH; Zhao Y; Yu SY; Lu Y
Acta Pharmacol Sin; 2024 Jan; 45(1):193-208. PubMed ID: 37749237
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer.
Cheng B; Ding K; Chen P; Ji J; Luo T; Guo X; Qiu W; Ma C; Meng X; Wang J; Yu J; Liu Y
Cancer Commun (Lond); 2022 Jan; 42(1):17-36. PubMed ID: 34981670
[TBL] [Abstract][Full Text] [Related]
19. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
20. HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila.
Teng L; Wang K; Chen W; Wang YS; Bi L
Pharmacol Res; 2020 Oct; 160():105086. PubMed ID: 32687951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
